SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision

🎯 Drug Targets

Browse 2 drug targets with druggability analysis, composite scores, and clinical context

2
Targets
0
High Druggability
0.51
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 2Low: 0Unknown: 0
Avg druggability score: 0.499
Clinical Pipeline
Approved: 1Phase III: 1Phase II: 0Phase I: 0Preclinical: 0
Total compounds: 5 · Approved: 2
Class All Classes Enzyme (35) Signaling Protein (25) Structural Protein (17) Protein (16) Gpcr (13) Ion Channel (12) Receptor (11) Transcription Factor (11) Ligand (10) Epigenetic Regulator (8) Transporter (8) Kinase (7) Other (4) Protease (4) Chaperone (4)
Druggability All Druggability Low (97) Medium (56) Undruggable (19) High (10) other (3)
Sort Score Druggability Gene A-Z Market Price
Filtered by: class=epigenetic_regulator, druggability=Medium — 2 results
DNMT1 DNA methyltransferase 1 Approved
Epigenetic Regulator Medium Druggability
Score
0.57
Drug.
0.52
Safety
0.30
Drugs
2
Hyps
6
Papers
36
Small molecule inhibitor of DNA methyltransferase activity
SIRT1 NAD-dependent protein deacetylase sirtuin-1 Phase III
Epigenetic Regulator Medium Druggability
Score
0.46
Drug.
0.48
Safety
0.73
Drugs
3
Hyps
2
Papers
44
SIRT1 activation via NAD+ precursors or allosteric activators deacetylates tau (reducing aggregation), enhances mitophagy, and restores circadian gene expression
Exchange | Dashboard